ALNY Alnylam Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-08 16:00
Why ALNY matters now
Alnylam Pharmaceuticals, Inc. (ALNY) is a US stock in Healthcare. The latest InvestLog snapshot shows $323.50 with +0.59% on the session and $43.19B in market capitalization; recent performance reads 1-month -5.51% and YTD -30.07%.
The latest financial table shown here is Q1 2026, with revenue of $1.17B, net income of $206.0M, and EPS of $1.51. Investors can compare that operating picture with valuation signals such as P/E 136.16 and FCF yield 1.7%.
The latest indexable market news headline is "Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $447.00; recent insider activity includes Cravatt Benjamin filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
136.16
PEG
0.64
P/B
34.37
P/S
8.66
EV/EBITDA
39.69
DCF Value
$-1,780.45
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.9%
Operating Margin
17.5%
Net Margin
13.5%
ROE
98.3%
ROA
11.3%
ROIC
19.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.17B | $206.0M | $1.51 |
| Q4 2025 | $1.10B | $186.4M | $1.37 |
| FY 2025 | $3.71B | $313.7M | $2.33 |
| Q3 2025 | $1.25B | $251.1M | $1.84 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$454.27
Target (Median)
$447.00
Target Range
$370.00 - $530.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.27
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.